| Literature DB >> 29916763 |
Yung-Chih Chiang1, Li-Yu Hu1,2,3, Jeremy Couper4,5, Chin-Chang Cheng2,6,7, Ling-Hsiang Wang1, Wei-Chun Huang2,6,7, Ti Lu1.
Abstract
About half of all patients with pulmonary hypertension (PH) experience psychological and emotional disturbances that affect their quality of life (QOL). There is a lack of studies exploring how psychiatric professionals can provide specific and effective mental health treatment to patients with PH. This study aimed to explore and understand the treatment experiences of patients with PH in Taiwan. We employed an exploratory qualitative design involving interviews with 17 patients with PH who were treated at Kaohsiung Veterans General Hospital in Taiwan. Participants were interviewed by a psychiatrist; the interviews were audiotaped and transcribed for thematic analysis by two researchers. We corroborate earlier findings showing that patients who have the rare disease PH often experience psychological or emotional disturbances throughout the treatment process. This study explored a model for psychiatric intervention based on patients' experience of having PH. We find that assessing and strengthening links to external resources can enhance patients' long-term coping abilities, and thereby help reduce their psychological and emotional disturbances and improve their QOL.Entities:
Keywords: lifestyle; psychosocial and behavioral factors in lung disease; pulmonary hypertension
Year: 2018 PMID: 29916763 PMCID: PMC6128075 DOI: 10.1177/2045894018787479
Source DB: PubMed Journal: Pulm Circ ISSN: 2045-8932 Impact factor: 3.017
Demographic data.
| Participant | Gender | Age (years) | Education level | Marital status | Employment | Time since diagnosis of PH (years) | Treatment |
|---|---|---|---|---|---|---|---|
| P01 | Male | 51 | Secondary | Married | Employed | 10 | ERA, Prostaglandins |
| P02 | Female | 48 | University | Married | Employed | 15 | ERA, Prostaglandins, sGC stimulator |
| P03 | Male | 71 | Secondary | Married | Retired | 5 | sGC stimulator |
| P04 | Female | 39 | Secondary | Divorced | Unemployed | 6 | ERA, Prostaglandins, sGC stimulator |
| P05 | Female | 47 | University | Never Married | Employed | 5 | PDE5 inhibitor |
| P06 | Male | 40 | University | Divorced | Unemployed | 9 | ERA, Prostaglandins, sGC stimulator |
| P07 | Female | 46 | Secondary | Married | Employed | 15 | ERA, Prostaglandins, sGC stimulator |
| P08 | Male | 84 | Secondary | Married | Retired | 3 | ERA, Prostaglandins |
| P09 | Female | 53 | Secondary | Married | Unemployed | 10 | ERA |
| P10 | Female | 76 | Uneducated | Widowed | Unemployed | 4 | ERA |
| P11 | Female | 37 | University | Married | Unemployed | 4 | PDE5 inhibitor, Prostaglandins |
| P12 | Female | 62 | Secondary | Never Married | Unemployed | 4 | ERA, PDE5 inhibitor |
| P13 | Female | 27 | Secondary | Never Married | Employed | 6 | PDE5 inhibitor, Prostaglandins |
| P14 | Female | 50 | Secondary | Never Married | Employed | 7 | sGC stimulator |
| P15 | Female | 63 | Primary | Married | Unemployed | 2 | ERA |
| P16 | Female | 71 | Secondary | Married | Retired | 2 | PDE5 inhibitor |
| P17 | Female | 46 | Secondary | Divorced | Unemployed | 2 | ERA |
P indicates the participant (refer to the “Patient Experiences” section in the main text).
PH, pulmonary hypertension; ERA, endothelin receptor antagonist; PDE5 inhibitor, phosphodiesterase type 5 inhibitor, sGC stimulator, soluble guanylyl cyclase stimulator.